Dalvir Gill | Source | CEO at TransCelerate BioPharma

Both BioCelerate and the FDA see SEND as a critical enabler for both single-study and cross-study analysis, and this collaboration helps the R&D ecosystem further validate decisions and diminish attrition earlier. Given that SEND is one of the FDA’s required standards for data submission, it is critical to maximize the value of datasets using this standard.